CDK4 and breast cancer: Importantly, the findings from pivotal phase 3 studies indicate that the combination of ET with CDK4/6 inhibitors is the current standard approach in the first-line treatment of HR-positive/HER2-negative metastatic BC [6,7,8,9,10].